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Abstract
Azithromycin (AZM) is a broad-spectrum antibiotic with anti-inflammatory and immunomodulatory properties. It is 
particularly used in chronic lung diseases including chronic obstructive pulmonary disease, asthma, interstitial lung 
diseases, bronchiectasis, and cystic fibrosis. AZM has not approved for the treatment of viral infections, but some 
study supported its antiviral activity. Recently, few studies are emphasized used AZM in combination with chloroquine/
hydroxychloroquine for the treatment of novel coronavirus disease-2019 (COVID-19). The present review highlighted 
uses, dosage, and adverse effects of AZM in COVID-19 based on available literature.
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Introduction
An outbreak of coronavirus disease-2019 
occurred in Wuhan, China in the month of December 
2019 and rapidly spread across the world [1], [2]. On 
March 11, 2020, the WHO declared COVID-19 as a 
pandemic disease [3]. In an early stage, infection is 
characterized mainly by respiratory symptoms such 
as cough, sore throat, fever, and fatigue [4]. On later 
stage, high viral replication, high inflammatory activity, 
and exacerbated immune response lead to a “cytokine 
storm,” which is responsible for complications, 
such as severe pneumonia and acute respiratory 
distress syndrome [5], with increased requirement of 
ventilatory support and intensive care unit admission 
[6]. About 80% of patients have mild disease and the 
overall case-fatality rate is about 2.3% but reaches 
8.0% in patients aged 70–79 years and 14.8% in those 
aged ≥80 years, but major concern is that number of 
asymptomatic carriers in the population, and thus, the 
mortality rate is probably overestimated [7]. Therefore, 
there is an urgent need for an effective treatment to 
treat symptomatic patients and decrease the duration 
of virus carriage to limit the transmission in the 
community. 
Till date, there is no specific treatment 
which is available to treat COVID-19. However, 
the backbone of the treatment strategy for 
COVID-19 is good quality supportive care as in 
any viral pneumonia. There is no current evidence 
from randomized controlled trial to recommend any 
specific anti-COVID-19 treatment for patients with 
suspected or confirmed COVID-19 infection. The 
clinicians are using various drugs such as antiviral 
drugs that include inhibitors against protease, 
integrase, and polymerase enzymes based on 
anecdotal data and some recent publications. 
Moreover, antiviral effects of azithromycin (AZM) 
have been attracted considerable attention [8]. 
There are various treatments being used to 
control COVID-19 based on previous experiences with 
other viral infections. In the present review, we aim to 
summarize the uses of AZM in COVID-19. 
Materials and Methods
Data sources
We performed thorough literature search on 
published studies between January 1, 2020, and April 
15, 2020. PubMed and Google Scholar databases 
were used to find articles providing information on the 
efficacy and safety of AZM in patients with COVID-19. 
No language restrictions were imposed. 
 Agrawal. Azithromycin in Coronavirus Disease-19: What We Know? 
Open Access Maced J Med Sci. 2020 Jun 25; 8(T1):92-96. 93
Inclusion and exclusion criteria 
The studies which describe used of AZM in 
COVID-19 and previous epidemic viruses such Ebola, 
severe acute respiratory syndrome, and Middle-East 
respiratory syndrome were selected. Meanwhile, 
studies which (a) duplicate publications, (b) full articles 
not available, (c) literature reviews, and (d) do not 
provided sufficient information or support regarding their 
recommendation of their proposed drugs or treatment 
process were excluded from the study. 
Results
A total of 170 articles initially identified. After 
removing duplicates, checking title, abstract, and full 
text 30 were found eligible based on the predetermined 
exclusion and inclusion criteria for this study. Among 
these three articles were relevant which showed used 
of AZM in COVID-19 patients as summarized in Table 1 
while rest of all articles were used for basic information. 
Discussion
AZM
AZM is a macrolide antibiotic with a 
15-membered lactone ring. It is broad-spectrum 
antibiotics with long serum half-life near about 68 
h and large volume of distribution [9]. AZM has 
excellent tissue penetration. In infected tissues, AZM 
concentrations are about 300-fold higher than in 
plasma, due to recruitment of leukocytes at the site 
of infection [10]. It also has anti-inflammatory activity, 
decreases pro-inflammatory cytokine and hastening 
of the macrophages phagocytosis ability [11]. Due to 
its antibacterial and anti-inflammatory effects, it is 
used for many chronic lung diseases including chronic 
obstructive pulmonary disease, asthma, interstitial lung 
diseases, bronchiectasis, and cystic fibrosis [12].
AZM as antiviral
Azithromycin effective against rhinovirus, 
respiratory syncytial virus, influenza virus, Zika virus 
and Ebola viruses [13], [14], [15], [16]. The mechanism 
is unknown. The multiple mechanisms have been 
proposed for antiviral activity observed with AZM. The 
antiviral activity may be mediated by amplification of 
the host’s interferon (IFN) pathway by inducing pattern 
recognition receptors, IFNs, and IFN-stimulated genes 
that lead to a reduction of viral replication [17], by 
directly acting on bronchial epithelial cells which reduce 
mucus secretion (19). Moreover, a recent quantum 
mechanical modeling suggests a potential role of AZM 
in COVID-19 by interfering with viral entry through 
binding interaction between coronavirus spike protein 
and host receptor angiotensin-converting enzyme-2 
protein; further, experimental work on this is necessary 
to confirm the model [18].
Clinical study
The symptoms of COVID-19 are similar to 
those seen in these lung infections; therefore, it is not 
surprising that AZM treatment was initiated early in the 
current pandemic of COVID-19. The use of AZM in 
25 of 138 patients who were suffer from COVID-19 in 
Wuhan, China, reported in a recent JAMA article [19].
First French clinical study
A French confirmed COVID-19 positive; 
36 patients (n = 20 in treatment group and n = 16 in 
control group) were enrolled in an open-label non-
randomized clinical trial. In the treatment group, 600 
mg HCQ daily was given to patients and their viral load 
in nasopharyngeal swabs was tested daily. On basis of 
clinical presentation of patients, six patients received 
AZM (500 mg on day 1 followed by 250 mg/day for the 
next 4 days) to prevent bacterial superinfection under 
daily electrocardiogram (ECG) control. Untreated 
patients from another center and cases refusing the 
protocol were included as negative controls. The 
presence and absence of virus at day 6 post-inclusion 
was considered the end point. The combination of 
hydroxychloroquine and AZM results in negative PCR 
results in nasopharyngeal samples was significantly 
Table 1: Clinical study of azithromycin in COVID-19
Study population Sample size Study design Treatments Results Reference
COVID-19 n=36
Treatment group n=20
Control group n=16
Observational open-
label non-randomized 
clinical trial
HCQ 200 mg, TID×10 days 
HCQ+AZM (500 mg D1 and 
250 mg D2-5)
At day 6 post-inclusion, virologically cured
HCQ+AZM: 100%
HCQ: 57.1%
Control: 12.5%
p<0.001
20
COVID-19 n=80 Uncontrolled 
non-comparative 
observational
HCQ 200 mg, TID×10 
days+AZM (500 mg D1 and 
250 mg D2-5)
Nasopharyngeal viral load tested by qPCR; 83% negative at day 
7 and 93% at day 8
Virus cultures from patient respiratory samples were negative in 
97.5% of patients at day 5
21
Suspected 
COVID-19; flu-like 
symptoms
n=636
Treatment group n=412
Control group n=224
Observational open-
label non-randomized 
HCQ 800 mg on D1 and 
400 mg D2-D7+AZM 500 
mg D1-D5 
HCQ+AZM: 1.9% of patients required hospitalization Control: 
5.4% of patients required hospitalization (p<0.0001)
Patients treated before versus after day 7 of symptoms required 
less hospitalization (1.17% and 3.2%, respectively, p<0.001)
22
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different between the two groups at days 3-4-5 and 
6 post-inclusion. At day 6 post-inclusion, 100% of 
patients treated with hydroxychloroquine and AZM 
were virologically cured compared to 57.1% in patients 
treated with hydroxychloroquine only and 12.5% in the 
control group (p < 0.001). Therefore, addition of AZM 
to hydroxychloroquine treatment results in significantly 
viral load reduction/disappearance in COVID-19 
patients. The limitations of study are small sample size, 
limited long-term outcome follow-up, and dropout of six 
patients from the study [20].
Second French clinical study
Gautret et al. conducted an uncontrolled 
non-comparative observational study in a cohort of 
80 confirmed COVID-19 patients. All patients received 
600 mg/day oral hydroxychloroquine sulfate for 10 
days combined with AZM (500 mg on day 1 followed by 
250 mg/day for the next 4 days). Patients with pneumonia 
and NEWS score ≥5, a broad-spectrum antibiotic 
(ceftriaxone), were added to hydroxychloroquine and 
AZM. Twelve-lead ECGs were performed on each 
patient before treatment and 2 days after treatment 
began. The median age of patients was 52 years 
(ranging from 18 to 88 years) and had at least one 
chronic condition such as hypertension, diabetes, and 
chronic respiratory disease. About 81.3% of patients 
had favorable outcome and were discharged from unit 
while only 15% required oxygen therapy during their 
stay. A rapid fall of nasopharyngeal viral load tested 
by quantitative polymerase chain reaction was noted, 
with 83% negative at day 7 and 93% at day 8. Virus 
cultures from patient respiratory samples were negative 
in 97.5% of patients at day 5. Moreover, patients were 
able to be rapidly discharged from infectious disease 
unit with a mean length of stay of 5 days. Therefore, a 
beneficial effect of coadministration of AZM along with 
hydroxychloroquine observed in COVID-19 patients [21].
Brazil telemedicine clinical study
A telemedicine study was conducted in Sao 
Paulo, Brazil, after the pandemic was officially declared 
in city. Patients with persistent flu-like symptoms 
(suspected COVID-19 infection), persisting for a period 
equal to or greater than 2 days, were first evaluated 
by the telemedicine team or by the emergency 
department medical doctor. Participants who did not 
need immediate hospitalization and azithromycin was 
not contraindications were invited to participate in the 
study. A total of 636 symptomatic outpatients enrolled 
in the study. The treatment group (n = 412) received 
hydroxychloroquine 800 mg on the 1st day and 400 mg 
for another 6 days and AZM 500 mg once daily for 5 
days. A total of 224 patients who refused to medications 
served as control group. The swab laboratory was 
not mandatory and chest computed tomography was 
performed according to medical judgment. All patients 
were followed daily by telemedicine consultations 
until the 5th day of symptoms, after that, patients 
were contacted twice a day until the 14th day of initial 
symptoms. In the treatment group, 1.9% of patients 
required hospitalization as compared to 5.4% of patients 
in the control group (p < 0.0001) which indicates 2.8 
times greater need for hospitalization compared to those 
without medication. An absolute risk reduction is 3.5% 
and a number needed to treat (NNT) is 28 to prevent 
one hospitalization. The patients treated before versus 
after day 7 of symptoms required less hospitalization 
(1.17% and 3.2%, respectively, p < 0.001). Comparing 
the early treatment (< 7 days of symptoms) to those 
without treatment (control group), the NNT was 23. 
Therefore, empirical treatment of hydroxychloroquine 
and AZM for suspected cases of COVID-19 reduces the 
need for hospitalization [22]. To sum up, Table 1 shows 
clinical studies of AZM in COVID-19. 
Adverse events
Common side effects of AZM include abdominal 
pain, diarrhea, constipation, nausea, dizziness, 
headaches, photosensitivity, or a skin rash [23]. 
Tinnitus and even hearing loss are associated with this 
medication [24], [25]. It should be avoided in patients 
with a history of Stevens-Johnson syndrome [26] and 
other serious skin reactions [27] as well as those with 
myasthenia gravis. Prolonged cardiac repolarization 
and prolongation of the QT interval can occur [28]. An 
ECG should be performed to assess the normal heart 
rhythm because the medication can cause arrhythmias. 
Patients with abnormal QT intervals, congenital 
long QT syndrome, a history of torsades de pointes, 
bradyarrhythmias, or heart failure may be at risk for 
fatal QT prolongation [29]. Elderly patients are more 
at risk. Abnormal liver function tests, hepatitis, hepatic 
necrosis, cholestatic jaundice, and hepatic failure 
have been reported with its use. AZM increased levels 
of theophylline and aminophylline, warfarin, digoxin, 
phenytoin, and statins. Nelfinavir increases serum 
concentration of AZM, so those receiving single oral 
doses need to have liver enzyme tests and hearing 
monitored [30].
Conclusion
The literature presented here provides a 
significant role of AZM in COVID-19 when combined 
with HCQ. It helps to reduce nasopharyngeal viral load, 
hospitalization and patients were able to be rapidly 
discharged from infectious disease unit. A well-designed 
randomized double-blind placebo control clinical trials 
are needed for further clarity and evidence. Results of 
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near future researches will assess safety data of its use 
to guide clinical usage during this pandemic.
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